Meeting
2023 ASCO Annual Meeting
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
Authors
Panagiotis A. Konstantinopoulos
Dana-Farber Cancer Institute, Boston, MA
Panagiotis A. Konstantinopoulos , Elizabeth Katherine Lee , SuChun Cheng , Alexandre Andre B. A. Da Costa , Andrea Elisabeth Wahner Hendrickson , Doga Gulhan , Bose Kochupurakkal , David Kolin , Elise C. Kohn , Joyce F. Liu , Elizabeth Stover , Jennifer Curtis , Hannah Sawyer , Madeline Polak , Dipanjan Chowdhury , Anniina Färkkilä , Alan D. D'Andrea , Geoffrey Shapiro , Ursula A. Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02595892
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5512)
DOI
10.1200/JCO.2023.41.16_suppl.5512
Abstract #
5512
Poster Bd #
207
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.
First Author: Sarah Shin
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2018 ASCO Annual Meeting
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
First Author: Charlie Gourley
Poster
2016 ASCO Annual Meeting
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase 2 study.
First Author: Ursula A. Matulonis